|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1994-6-9
|
|
pubmed:abstractText |
2-chlorodeoxyadenosine (2-CDA) is a new purine analogue which has been shown to be highly active in lymphoproliferative disorders. In this clinical trial we assessed 2-CDA toxicity and response rate in patients with various haematological malignancies who were heavily pre-treated and mostly refractory to standard treatment regimens.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
57-64
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7909685-Acute Disease,
pubmed-meshheading:7909685-Adolescent,
pubmed-meshheading:7909685-Adult,
pubmed-meshheading:7909685-Aged,
pubmed-meshheading:7909685-Aged, 80 and over,
pubmed-meshheading:7909685-Bone Marrow Diseases,
pubmed-meshheading:7909685-Chronic Disease,
pubmed-meshheading:7909685-Cladribine,
pubmed-meshheading:7909685-Female,
pubmed-meshheading:7909685-Humans,
pubmed-meshheading:7909685-Immunocompromised Host,
pubmed-meshheading:7909685-Incidence,
pubmed-meshheading:7909685-Leukemia,
pubmed-meshheading:7909685-Lymphoma,
pubmed-meshheading:7909685-Male,
pubmed-meshheading:7909685-Middle Aged,
pubmed-meshheading:7909685-Opportunistic Infections,
pubmed-meshheading:7909685-Prospective Studies,
pubmed-meshheading:7909685-Treatment Outcome
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
|
|
pubmed:affiliation |
Institute of Medical Oncology, University of Berne, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
